The Brazilian healthcare regulator Anvisa said on Monday (Dec.4) it is restricting the use of a dengue vaccine that its own producer -French drug company Sanofi – said it could worsen the disease in some cases. Anvisa reccomends that people who have never been infected with dengue to not take the vaccine.
The World Health Organisation said it is conducting a full review of data on the vaccine, commercially known as Dengvaxia. In the meantime, the WHO recommended it be used only in people who had a prior infection with dengue.
Sanofi explained its “new findings” at a news conference in Manila but did not say why action was not taken after a WHO report in mid-2016 that identified the risk.